Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 8/28/14  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Hiram S. Cody III

Wrong Dr. Hiram S. Cody III?


Local Address: NY, New York, United States
Memorial Sloan-Kettering Cancer Center
1275 York Avenue Box # 460
New York , New York 10065
United States

Company Description: Memorial Sloan-Kettering Cancer Center is the world's oldest and largest institution devoted to prevention, patient care, research and education in cancer. Our...   more

Employment History

Board Memberships and Affiliations


  • MD
  • Columbia University College of Physicians and Surgeons
62 Total References
Web References
American Society of Breast Surgeons - About Us - Board of Directors, 5 May 2012 [cached]
Hiram S. Cody, III, MD, FACS Secretary/Treasurer
Hiram S. Cody III MD is an Attending Surgeon on the Breast Service, Department of Surgery, at Memorial Sloan-Kettering Cancer (MSKCC), and Professor of Clinical Surgery at Weill Cornell Medical College, in New York. He is a graduate of Columbia University College of Physicians and Surgeons, completed Residency in General Surgery at The Roosevelt Hospital, and Fellowship in Surgical Oncology at MSKCC. His clinical research interests have included patterns of loco-regional spread and long-term outcomes of breast cancer surgery, the impact of screening mammography, and sentinel lymph node biopsy. He is Principal Investigator of MSKCC's Sentinel Lymph Node Biopsy Program, has served as Acting Chief of MSKCC's Breast Service, and is active in local, national, and international organizations. He is Editor of the journal Breast Diseases, on the Editorial Boards of the Journal of Clinical Oncology, Annals of Surgical Oncology and Surgery, reviews for 15 other journals, and was Editor of the multi-author textbook Sentinel Lymph Node Biopsy. He is the author of more than 200 peer-reviewed papers, reviews, editorials and book chapters. For the American Society of Breast Surgeons, he was Program Chair of the 9th Annual Meeting, he is a member of the Board of Directors, and he currently serves as Secretary/Treasurer.TOP OF PAGE
Hiram S. Cody, III, MD, FACS Secretary/Treasurer, 2011 - 2012
Women's Health Issues - Breast Cancer Lymph Node Biopsy May Need Closer Look, 17 Nov 2008 [cached]
In the study, a team led by Dr. Hiram S. Cody III, a professor of clinical surgery at Memorial Sloan-Kettering Cancer Center in New York City, analyzed a population of 368 patients who were originally diagnosed with breast cancer in the 1970s. At the time, these patients were judged to be free of cancerous cells on the basis of a single tissue slice (standard procedure at that time). As a result of that diagnosis, these patients received no follow-up treatment for their disease.
Each of these patients was then monitored over the following 20 years or so. Cody and his team retrospectively reanalyzed the decades-old tissue samples using modern techniques. They then assessed how many of the slices did, in fact, contain cancerous cells, and whether those stray cancerous cells had affected the women's survival.
"What we found was that among these patients, 23 percent were converted to node-positive [cancer status], and among those who were converted, their survival was worse than among patients who remained node-negative," said Cody.
"The 23 percent number is very significant, because it argues that if pathologists just do one section, you may want to ask them to do more," he explained. "We think the information you get by doing more is significant."
According to Cody, 30 years ago the standard of care for breast cancer patients was complete dissection of the axillary lymph nodes (those found under the armpit) followed by cell-shape analysis using a single tissue slice from each node.
That reduction in work per node has a real payoff, because pathologists can delve much deeper into each sample, Cody explained.
"Because you remove fewer nodes, you can study them more carefully, and we argue that the information you get by doing that is prognostically significant," he said.
Current guidelines from the College of American Pathologists recommend analyzing one tissue slice per biopsied lymph node, Cody noted. Yet for years, he said, physicians have known that the more carefully one looks, the more cancerous cells one can find.
Cody noted one "significant caveat" to this study: Because breast cancer survival and treatment regimens have changed so dramatically over the past 30 years, this study says nothing about the prognostic implication of micrometastases discovered today. That will require prospective studies, several of which are ongoing.
Nevertheless, he said, "because we don't know the results of those studies yet, studies like our own may be the best available evidence at present, and our study suggests these micrometastases are prognostically significant."
SOURCES: Hiram S. Cody III, M.D., attending surgeon, professor, clinical surgery, Breast Service, department of surgery, Memorial Sloan-Kettering Cancer Center, New York City; Stephen F. Sener, M.D., professor, surgery, Northwestern University Feinberg School of Medicine, Chicago; April 10, 2008, Journal of Clinical Oncology
The increasing incident rates for DCIS "mirror what all of us have been seeing in practice for the last decade", says Dr. Hiram Cody, a breast cancer specialist at Sloan-Kettering Cancer Center in New York.
Dallas Surgical Group [cached]
“APBI appears to be safe and effective treatment for properly selected breast conservation patients,†says Dr. Hiram S. Cody III, Attending Surgeon, Breast Service Department of Surgery, Memorial Sloan-Kettering Cancer Center and Professor of Clinical Surgery, Weil Cornell Medical College. Dr. Cody, who is also a member of the Executive Committee and Board of Directors for ASBrS, notes that the ASBrS continues to support its Consensus Statement on APBI and guidelines for patient selection (August 15, 2011 revision): (
However, Dr. Cody also states, “We wish to emphasize that although the six year results of APBI are encouraging, they do not conclusively establish equivalence with WBI, for which the supporting data include multiple randomized trials with follow-up exceeding 20 years, and meta-analyses that conclusively link local control and survival.
prIME Downloadable Slides from Examining Locoregional Control in Early Breast Cancer, 20 Nov 2013 [cached]
Hiram Cody, III, MD, FACS, Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Hiram Cody, III, MD, FACS, Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Other People with the name "Cody":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.